Silvia Leoncini Selected Research

Methyl-CpG-Binding Protein 2

4/2021	Circulating 4-F4t-Neuroprostane and 10-F4t-Neuroprostane Are Related to MECP2 Gene Mutation and Natural History in Rett Syndrome.
1/2020	Brain protein changes in Mecp2 mouse mutant models: Effects on disease progression of Mecp2 brain specific gene reactivation.
10/2017	Proteomic analysis of the Rett syndrome experimental model mecp2Q63X mutant zebrafish.
3/2017	Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation.
1/2017	Persistent Unresolved Inflammation in the Mecp2-308 Female Mutated Mouse Model of Rett Syndrome.
4/2016	Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome.
1/2016	MECP2 Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison with Rett Syndrome.
1/2015	Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ω-3 PUFAs.
10/2014	Scavenger Receptor B1 oxidative post-translational modifications are responsible for its loss in Rett syndrome.
8/2014	Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvia Leoncini Research Topics

Disease

32	Rett Syndrome (Rett's Disorder) 01/2022 - 08/2009
14	Neurodevelopmental Disorders 04/2021 - 08/2009
7	Hypoxia (Hypoxemia) 11/2010 - 01/2003
6	Disease Progression 04/2021 - 07/2011
4	Inflammation (Inflammations) 03/2017 - 11/2014
4	Acute-Phase Reaction 03/2017 - 01/2013
4	Autism Spectrum Disorder 11/2016 - 01/2013
4	Autistic Disorder (Autism) 11/2016 - 01/2013
3	Brain Diseases (Brain Disorder) 07/2018 - 04/2016
2	Apnea 01/2022 - 01/2014
2	Intellectual Disability (Idiocy) 01/2020 - 08/2009
1	Mood Disorders (Mood Disorder) 01/2020
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020
1	Globoid Cell Leukodystrophy (Krabbe Disease) 01/2019
1	Nervous System Diseases (Neurological Disorders) 07/2018
1	Inborn Genetic Diseases (Disease, Hereditary) 10/2017
1	Cognitive Dysfunction 12/2016
1	Down Syndrome (Down's Syndrome) 12/2016
1	Constipation 01/2016
1	Lubs X-linked mental retardation syndrome 01/2016
1	CDKL5 deficiency disorder 09/2015
1	Type 2 Diabetes Mellitus (MODY) 08/2013
1	Hypertension (High Blood Pressure) 08/2013
1	Neuroblastoma 11/2010
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 03/2009
1	Ischemia 03/2009

Drug/Important Bio-Agent (IBA)

23	Methyl-CpG-Binding Protein 2IBA 04/2021 - 08/2009
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2005
10	IronIBA 01/2022 - 01/2003
6	Biomarkers (Surrogate Marker)IBA 04/2021 - 12/2011
5	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2015 - 07/2012
4	LipidsIBA 09/2015 - 12/2011
3	Biological ProductsIBA 04/2021 - 01/2018
3	NeuroprostanesIBA 01/2019 - 03/2009
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2017 - 01/2014
3	Fatty Acids (Saturated Fatty Acids)IBA 11/2015 - 07/2014
3	F2-Isoprostanes (F2 Isoprostanes)IBA 11/2010 - 06/2007
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 02/2013
2	IsoprostanesIBA 01/2019 - 03/2009
2	CD5 AntigensIBA 03/2017 - 01/2017
2	CytokinesIBA 03/2017 - 01/2015
2	high density lipoprotein receptorsIBA 10/2014 - 07/2013
2	Scavenger Receptors (Scavenger Receptor)IBA 10/2014 - 07/2013
2	AntioxidantsIBA 02/2013 - 10/2005
2	adrenic acid (7,10,13,16-docosatetraenoic acid)IBA 01/2013 - 12/2011
2	Adenosine Triphosphate (ATP)IBA 01/2010 - 06/2007
1	10-F4t-neuroprostaneIBA 04/2021
1	4-F4t-neuroprostaneIBA 04/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	Mirtazapine (Rexer)FDA LinkGeneric 01/2020
1	Antidepressive Agents (Antidepressants)IBA 01/2020
1	GalactosylceramidaseIBA 01/2019
1	Interleukin-10 (Interleukin 10)IBA 03/2017
1	Complement System Proteins (Complement)IBA 03/2017
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2017
1	AlbuminsIBA 01/2017
1	Kininogens (Kininogen)IBA 01/2017
1	Pregnancy-Associated alpha 2-Macroglobulins (alpha 2 Macroglobulin)IBA 01/2017
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2017
1	Transferrin (beta 2 Transferrin)IBA 01/2017
1	Vitamin D-Binding ProteinIBA 01/2017
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2017
1	alpha 1-Antitrypsin (alpha 1 Antitrypsin)IBA 01/2017
1	Blood Proteins (Serum Proteins)IBA 11/2016
1	NucleotidesIBA 04/2016
1	Volatile Fatty AcidsIBA 01/2016
1	Actins (F Actin)IBA 01/2014
1	Glutathione Disulfide (GSSG)FDA LinkGeneric 01/2014
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2014
1	Immunoglobulin M (IgM)IBA 01/2014
1	Glutathione (Reduced Glutathione)IBA 08/2013
1	Caspase 3 (Caspase-3)IBA 08/2013
1	MethemoglobinIBA 08/2013
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 02/2013
1	alpha-1-microglobulinIBA 01/2013
1	Fibrinogen (Factor I)FDA Link 01/2013
1	HaptoglobinsIBA 01/2013
1	Complement C3 (C3 Complement)IBA 01/2013
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2013
1	ChromatinIBA 01/2013
1	Carrier Proteins (Binding Protein)IBA 01/2013
1	ProteomeIBA 01/2013
1	Docosahexaenoic AcidsIBA 07/2011
1	Neuroprotective AgentsIBA 03/2009
1	Oxygen (Dioxygen)IBA 03/2009
1	NitrogenIBA 03/2009
1	MelatoninIBA 03/2009
1	Free RadicalsIBA 03/2009
1	Superoxides (Superoxide)IBA 06/2004
1	Immunoglobulin G (IgG)IBA 06/2004

Therapy/Procedure

1	Duration of Therapy 01/2020
1	Therapeutics 07/2012
1	Ligation 03/2009